Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003299 · ClinicalTrials.gov registry record · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
A NA study of Aortic Stenosis and Aortic Stenosis, Severe, sponsored by Edwards Lifesciences.
- Recruiting
- Registry status
- NA
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT03003299: Recruiting NA study of Aortic Stenosis and Aortic Stenosis, Severe, sponsored by Edwards Lifesciences.
NCT03003299 is a NA study of Aortic Stenosis and Aortic Stenosis, Severe that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 125 participants, below the 1,357-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03003299, a NA study of Aortic Stenosis and Aortic Stenosis, Severe, is actively recruiting participants, sponsored by Edwards Lifesciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Primary Outcome
Number of patients that died and/or had a stroke
Conditions Studied
Interventions
- DEVICE Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Study Locations (20)
California
- University of California Los Angeles - Los Angeles
- Sutter Medical Center - Sacramento
- Kaiser Permanente San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Illinois
- Northwestern University Hospital - Chicago
- Rush University Medical Center - Chicago
- Northshore University HealthSystem - Evanston
- Prairie Education and Research Cooperative - Springfield
Florida
- JFK Medical Center/ Atlantic Clinical Research Collaborative - Atlantis
- University of Florida, Gainesville - Gainesville
Michigan
- Henry Ford Hospital - Detroit
- William Beaumont Hospital - Royal Oak
Minnesota
- University of Minnesota Medical Center - Minneapolis
- Mayo Clinic - Rochester
Arizona
- Banner University Medical Center - Phoenix
Colorado
- UC Health Northern Colorado/Medical Center of the Rockies - Loveland
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2017-01-05 |
| Est. Completion | 2038-04 |
| Phase | NA |
What NCT03003299 shows while recruiting
NCT03003299 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 1,357-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which Edwards SAPIEN 3/SAPIEN 3 Ultra THV is the first listed.
NCT03003299 names 20 study sites across 11 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT03003299 about?
NCT03003299 is a clinical study titled "PARTNER 3 Trial - Aortic Valve-in-Valve". This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
What is the current status of trial NCT03003299?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2017-01-05. Estimated completion is 2038-04.
What conditions does trial NCT03003299 study?
This clinical trial studies the following conditions: Aortic Stenosis, Aortic Stenosis, Severe.
What interventions are being tested in trial NCT03003299?
The interventions under investigation include: Edwards SAPIEN 3/SAPIEN 3 Ultra THV (DEVICE).
Who is sponsoring clinical trial NCT03003299?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03003299 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03003299's enrollment target sits among peer trials
125 18th of 26 higher than 9 of 26 other Aortic Stenosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aortic Stenosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacement Fibrosis
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
-
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
RECRUITING · NA
-
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
RECRUITING · NA
-
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)
ACTIVE NOT RECRUITING · NA
-
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03107520 · 125 participants · Early Phase 1
Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI